Evaluation of Zika rapid tests as aids for clinical diagnosis and epidemic preparedness

Boeras, Debi; Diagne, Cheikh Tidiane; Pelegrino, José Luis; Grandadam, Marc; Duong, Veasna; Dussart, Philippe; Brey, Paul T.; Ruiz, Didye; Adati, Marisa Coelho; Wilder‐Smith, Annelies; Falconar, Andrew K.; Romero, Claudia Moreno; Guzmán, María G.; Hasanin, Nagwa; Sall, Amadou Alpha; Peeling, Rosanna W.

doi:10.1016/j.eclinm.2022.101478

Cited by 5 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Decentralized testing using multiplex LFTs (xLFTs) with data capture and reporting may provide early alerts of outbreaks, help to detect infections and antimicrobial resistance, and support effective triaging in health systems. For example, xLFTs can detect multiple targets and differentiate between multiple flaviviruses 160 , sexually transmitted infections and drugs. xLFTs have also been developed to distinguish SARS-CoV-2, influenza and their co-infections 161 , and HIV/syphilis xLFTs 162 are commercially available.…”

Section: Multiplexingmentioning

confidence: 99%

Lateral flow test engineering and lessons learned from COVID-19

et al. 2023

Self Cite

View full text Add to dashboard Cite

The acceptability and feasibility of large-scale testing with lateral flow tests (LFTs) for clinical and public health purposes has been demonstrated during the COVID-19 pandemic. LFTs can detect analytes in a variety of samples, providing a rapid read-out, which allows selftesting and decentralized diagnosis. In this Review, we examine the changing LFT landscape with a focus on lessons learned from COVID-19. We discuss the implications of LFTs for decentralized testing of infectious diseases, including diseases of epidemic potential, the 'silent pandemic' of antimicrobial resistance, and other acute and chronic infections. Bioengineering approaches will play a key part in increasing the sensitivity and specificity of LFTs, improving sample preparation, incorporating nucleic acid amplification and detection, and enabling multiplexing, digital connection and green manufacturing, with the aim of creating the next generation of high-accuracy, easy-to-use, affordable and digitally connected LFTs. We conclude with recommendations, including the building of a global network of LFT research and development hubs to facilitate and strengthen future diagnostic resilience. Sections• Bioengineering approaches, such as the use of nano-and quantum materials, nucleic-acid-based LFTs, CRISPR and machine learning, will improve the sensitivity, specificity, multiplexing and connectivity features of LFTs.• We recommend investing in an international LFT research and development hub network to spearhead the development of a pipeline of innovative bioengineering approaches to design next-generation LFTs.

show abstract

Section: Multiplexingmentioning

confidence: 99%

Lateral flow test engineering and lessons learned from COVID-19

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…The APC guidance for continued test development and standardised evaluation mechanism using a global network of biobanking sites resulted in three tests being approved by the UNICEF Product Reference Group as having the required performance for procurement. 76,77 Despite these initiatives, a critical challenge will be how to sustain manufacturing capacity for rapid tests in between disease outbreaks. The inconsistent and uncertain demand for diagnostics to detect diseases of epidemic potential makes it challenging for companies to maintain production lines in readiness for an outbreak.…”

Section: Develop New Funding and Randd Models For Test Developmentmentioning

confidence: 99%

Section: Moving Forward: Collaborations Among Test Developers Governm...mentioning

confidence: 99%

Lessons from COVID-19 for improving diagnostic access in future pandemics

Peeling

Sia

2023

Lab Chip

Self Cite

View full text Add to dashboard Cite

show abstract

“…During the 2016 Zika Virus (ZIKV) PHEIC, UNICEF supported the development and validation of point of care rapid diagnostic tests for ZIKV (tools which do not exist for monkeypox). 12 13 However, since they were developed there has not been a significant ZIKV outbreak where they have been needed. Something similar happened with Ebola diagnostics: these were commercialised during the 2014–2015 PHEIC, but then the manufacturers exited the market due to low/no demand in subsequent years.…”

mentioning

confidence: 99%

“…There are other important lessons from prior PHEIC responses that may be instructive as we grapple with these questions. During the 2016 Zika Virus (ZIKV) PHEIC, UNICEF supported the development and validation of point of care rapid diagnostic tests for ZIKV (tools which do not exist for monkeypox) 1213. However, since they were developed there has not been a significant ZIKV outbreak where they have been needed.…”

mentioning

confidence: 99%